Ehave Appoints Board-Certified Gastroenterologist And Licensed Physician Dr. Rahul Dixit To Its Medical Advisory Board
Ehave, Inc. (OTC Pink: EHVVF) announced the addition of Dr. Rahul Dixit to its Medical Advisory Board. Dr. Dixit, a Gastroenterology Specialist with over 17 years in the medical field, will advise on human trials for cognitive and psychedelic opportunities and mental health analytical platforms. His expertise in gastrointestinal ailments, particularly those linked to mental health, aligns with Ehave's focus on digital therapeutics for brain disorders. CEO Ben Kaplan expressed confidence in Dr. Dixit's valuable contributions as the company expands its operations.
- Dr. Rahul Dixit's extensive medical background strengthens the advisory team.
- His expertise in the relationship between mental health and gastrointestinal issues is beneficial for Ehave's focus.
- The addition of Dr. Dixit may enhance credibility and attract further investment.
- Concerns may arise regarding continuity and experience gaps in the advisory board after Dr. Dixit's appointment.
MIAMI, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today Dr. Rahul Dixit has agreed to join the Company's Medical Advisory Board. As a member of Ehave’s Medical Advisory Board, Dr. Dixit’s primary responsibilities will be to assist and advise the Company on human trials for its cognitive and psychedelic opportunities, as well as assist and advise the Company on mental health analytical platforms.
Rahul Dixit, MD Dr. Rahul Dixit, MD is a Gastroenterology Specialist with over 17 years of experience in the medical field. He graduated from the University of Maryland School of Medicine; he completed his residency in Internal Medicine, and a double fellowship in Gastroenterology, at the University of Miami and Hepatology/Liver Transplant at Johns Hopkins Hospital.
As a student, Rahul Dixit accumulated numerous honors, including the Distinguished Medical Student Service Award. He graduated in the top 1 percent of his undergraduate class and received the Phi Beta Kappa Award. Thanks to his outstanding academic achievements, he is one of the most sought out providers in the medical field.
Dr. Dixit is certified by the American Board of Internal Medicine in both Gastroenterology and Internal Medicine. He has been widely published in numerous medical journals. Recently, Dr. Dixit was awarded "Top Doc" in LA Magazine 2020.
For the past decade, Dr. Dixit has accelerated his business interests as an avid angel investor in biotech pharma and health supplement space. He is a healthcare advisor for many companies including BirlaDK Capital Advisors, G-Plans, Uniquely You, and DNA Analytical Services. He also co-founded Manas Ventures, a highly successful herbal and cannabis focused Biotech venture fund. Dr. Dixit has continued to research and write papers that not only improve his skills and ability to treat patients but, also, adds to the information available to gastroenterologists around the world.
Dr. Rahul Dixit said, “I’m very excited to be a part of Ehave and add to what they have quickly and greatly accomplished in such short time. We know that the gastrointestinal (GI) tract and gut has its own nervous system called the enteric system which is made up of trillions of organisms.” Dr. Dixit continued, “Anywhere from 10
Ben Kaplan, CEO of Ehave, Inc. said, “Ehave is very fortunate to include such an esteemed medical professional as Dr. Dixit as a member of our Medical Advisory Board. His credentials and experience make him a perfect fit for Ehave. We look forward to Dr. Dixit's expert as we expand our mental health analytical platform and enter clinical trials."
About Ehave, Inc.
Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it's a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
For Investors Relations, please contact:
Gabe Rodriguez
Phone: (623) 261-9046
Email: ir@ehave.com
FAQ
What is the significance of Dr. Rahul Dixit joining Ehave's Medical Advisory Board?
What are Dr. Dixit's qualifications related to his new role at Ehave?
How might Dr. Dixit's background impact Ehave's clinical trials?
What technologies does Ehave focus on for treating mental health disorders?
